Hologic

570 articles with Hologic

• Hologic Announces Preliminary Financial Results for First Quarter of Fiscal 2021

  1/8/2021

  Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 26, 2020.

• Hologic to Announce Financial Results for the First Quarter of Fiscal 2021 on Wednesday, January 27, 2021

  1/8/2021

  Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2021 on Wednesday, January 27, after the market closes.

• Hologic to Acquire Biotheranostics, Leader in Molecular Tests for Breast and Metastatic Cancers, for Approximately $230 Million

  1/5/2021

  – Transaction Accelerates Hologic’s Entry into Oncology Growth Market, Provides New Lab Capabilities – – Hologic’s Commercial Resources, Expertise in Molecular Automation Expected to Boost Biotheranostics Growth –

• Hologic to Acquire SOMATEX, Leader in Biopsy Site Markers and Localization Technologies, for $64 Million

  1/4/2021

  Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health, announced today it has completed the acquisition of SOMATEX Medical Technologies GmbH, a leader in biopsy site markers and localization technologies, for approximately $64 million.

• Hologic to Webcast Presentation at the 39th Annual J.P. Morgan Healthcare Conference

  12/28/2020

  Hologic to Webcast Presentation at the 39 th Annual J.P. Morgan Healthcare Conference

• Hologic Receives FDA Clearance for Latest Breakthrough in Early Breast Cancer Detection, Genius AI™ Detection

  12/1/2020

  Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health, today announced U.S. Food and Drug Administration (FDA) clearance and commercial availability of the Company’s Genius AI™ Detection technology, a new deep learning-based software designed to help radiologists detect subtle potential cancers in breast tomosynthesis images.

• Hologic to Showcase Products Across Breast Cancer Screening, Biopsy, Surgery and Treatment at Virtual RSNA 2020

  11/27/2020

  Hologic, Inc. (Nasdaq: HOLX) will virtually showcase its extensive portfolio of breast and skeletal health products, including screening, surgical, interventional, ultrasound and skeletal solutions, at the 106 th Scientific Assembly and Annual Meeting of the Radiological S

• Hologic to Webcast Presentation at Upcoming Virtual Investor Conference

  11/25/2020

  Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present virtually at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2 at 4:20 p.m. Eastern Time.

• Aptima HIV-1 Quant Dx Assay Receives Additional FDA Approval for Use as an Aid in the Diagnosis of HIV Infection

  11/20/2020

  Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has approved a diagnostic claim for its HIV-1 (human immunodeficiency virus type 1) viral load monitoring assay.

• Hologic Announces Financial Results for Fourth Quarter of Fiscal 2020

  11/4/2020

  Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal fourth quarter ended September 26, 2020.

• Hologic Awarded U.S. Government Contract to Expand COVID-19 Test Production Capacity

  10/30/2020

  Hologic, Inc. (Nasdaq: HOLX) announced today that it has been awarded a $119 million contract from the United States government to expand its production capacity for COVID-19 molecular tests.

• Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2020 on Wednesday, November 4, 2020

  10/7/2020

  Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2020 on Wednesday, November 4, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing 888-204-4368 (in the United States and Canada) or +1 323-994-

• FDA Amends Emergency Use Authorization for Hologic’s Aptima SARS-CoV-2 Assay to Include COVID-19 Testing of Asymptomatic Individuals, Symptomatic Sample Pooling

  10/6/2020

  Hologic, Inc. (Nasdaq: HOLX) announced today that its Aptima® SARS-CoV-2 assay, which initially received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in May, is now authorized for testing of individuals without symptoms or other reasons to suspect COVID-19 infection.

• Hologic Granted FDA Emergency Use Authorization for Asymptomatic COVID-19 Testing with Panther Fusion SARS-CoV-2 Assay

  9/28/2020

  Hologic, Inc. (Nasdaq: HOLX) announced today that its Panther Fusion® SARS-CoV-2 assay has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for testing of individuals without symptoms or other reasons to suspect COVID-19 infection. Hologic

• Hologic Announces Pricing of Offering of $950 Million of 3.250% Senior Notes Due 2029

  9/14/2020

  Hologic, Inc. (Nasdaq: HOLX) announced today that it has priced its previously announced private offering of $950 million aggregate principal amount of 3.250% senior notes due 2029 at an issue price of $1,000 per $1,000.

• Hologic Announces Offering of $950 Million of Senior Notes Due 2029

  9/14/2020

  Hologic, Inc. (Nasdaq: HOLX) announced today that it has launched, subject to market and other conditions, a private offering of $950 million aggregate principal amount of senior notes due 2029. Hologic intends to use the proceeds of the offering and available cash to refinance its existing 4.375% senior unsecu

• Hologic to Webcast Presentations at Upcoming Investor Conferences - Sep 04, 2020

  9/4/2020

  Hologic, Inc. announced that the Company will present at these upcoming virtual investor conferences

• Hologic to Acquire Acessa Health, Innovator in Minimally Invasive Solutions for Treatment of Fibroids

  8/25/2020

  Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that it has acquired Acessa Health Inc., a privately-held innovator in minimally invasive treatment for fibroids, for approximately $80 million in cash plus contingent payments based on future revenue growth.

• Hologic Announces 'Back to Screening' Campaign Encouraging Women to Prioritize Scheduling Annual Mammograms

  8/20/2020

  Campaign offers a chance to attend a private, virtual performance by GRAMMY®Award-winning artist and breast cancer survivor Sheryl Crow   [20-August-2020]   MARLBOROUGH, Mass. , Aug. 20, 2020 /PRNewswire/ -- WHAT:  At the start of the COVID-19 pandemic, many health officials, professional societies and patient a

• Hologic Launches Validated Pooling Protocol for COVID-19 Testing

  8/11/2020

  In Time of Extraordinary Need, New Protocol Expected to Help Laboratories Deliver Greater Quantities of Highly Accurate Molecular Test Results and Reduce Turnaround Times